768 research outputs found
Farming in the "New Economy" : An Australian Perspective
Barriers to trade between countries have reduced through the general Agreement on Tariffs and Trade (GATT) and the World Trade Organisation (WTO). The nature of trade between businesses is also changing dramatically through developments in Information Technology but also due to adoption of quality assurance and new approaches to supply chain management. The impacts of this "New Economy" vary around the world. This paper considers the implications of these developments for Australian farmers. Whilst these changes can be regarded as generally advantageous to Australian farmers, they may be disadvantaged in some areas because of the relatively small size of the Australian farming sector, its geographical dispersion, the advent of a range of new technologies and the structure of agribusinesses. The potential changes to the nature of farming and farm management skills are discussed.Farm Management,
Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinicianās perspective
Several studies have provided ample evidence of a clinically significant interobserver variation of the histological diagnosis of glioma. This interobserver variation has an effect on both the typing and grading of glial tumors. Since treatment decisions are based on histological diagnosis and grading, this affects patient care: erroneous classification and grading may result in both over- and undertreatment. In particular, the radiotherapy dosage and the use of chemotherapy are affected by tumor grade and lineage. It also affects the conduct and interpretation of clinical trials on glioma, in particular of studies into grade II and grade III gliomas. Although trials with central pathology review prior to inclusion will result in a more homogeneous patient population, the interpretation and external validity of such trials are still affected by this, and the question whether results of such trials can be generalized to patients diagnosed and treated elsewhere remains to be answered. Although molecular classification may help in typing and grading tumors, as of today this is still in its infancy and unlikely to completely replace histological classification. Routine pathology review in everyday clinical practice should be considered. More objective histological criteria for the grade and lineage of gliomas are urgently needed
Farm Management - Bugger the roots, where is the future?
The Farm Management discipline has long been closely aligned with agricultural economics. The question we raise is not where either discipline came from but where is Farm Management going. The impact of globalisation, the rising tide of deregulation and chain reversal mean that farm management professionals who have traditionally focused on optimisation of activities at a farm level are now commonly expected to use sociology and management science to explain economic organisation and performance on farms. They also are required to look at relationships in the value chain(s) in which the farm sits. This paper will analyse the implications of such change for Farm Management professionals.Farm Management, value chains, Farm Management,
The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in <i>IDH</i>-mutant gliomas
The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in <i>IDH</i>-mutant gliomas
<i>MGMT </i>promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas
<i>MGMT </i>promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas
Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial
BACKGROUND: Temporal muscle thickness (TMT) was described as surrogate marker of skeletal muscle mass. This study aimed to evaluate the prognostic relevance of TMT in patients with progressive glioblastoma.
METHODS: TMT was analyzed on cranial magnetic resonance images of 596 patients with progression of glioblastoma after radio-chemotherapy enrolled in the EORTC 26101 trial. An optimal TMT cutoff for overall survival (OS) and progression free survival (PFS) was defined in the training cohort (n=260, phase 2). Patients were grouped as "below" or "above" the TMT cutoff and associations with OS and PFS were tested using the Cox model adjusted for important risk factors. Findings were validated in a test cohort (n=308, phase 3).
RESULTS: An optimal baseline TMT cutoff of 7.2 mm was obtained in the training cohort for both OS and PFS (AUC=0.64). Univariate analyses estimated a hazard ratio (HR) of 0.54 (95% CI: 0.42, 0.70, p<0.0001) for OS and a HR of 0.49 (95% CI: 0.38, 0.64, p<0.0001) for PFS for the comparison of training cohort patients above versus below the TMT cutoff. Similar results were obtained in Cox models adjusted for important risk factors with relevance in the trial for OS (HR of 0.54, 95% CI: 0.41, 0.70, p<0.0001) and PFS (HR of 0.47, 95% CI: 0.36, 0.61, p<0.0001). Results were confirmed in the validation cohort.
CONCLUSION: Reduced TMT is an independent negative prognostic parameter in patients with progressive glioblastoma and may help to facilitate patient management by supporting patient stratification for therapeutic interventions or clinical trials
Predictive and prognostic markers in neurooncology
Abstract Over the past few years molecular assays have been introduced to aid in typing and grading of gliomas. This is the result of improved understanding of these tumors at the molecular level. In particular, the presence or absence of combined 1p/19 loss in oligodendroglial tumors, epidermal growth factor receptor amplification, epidermal growth factor receptor vIII mutations in grade III tumors and glioblastoma multiforme, and MGMT promoter gene methylation in glioblastoma multiforme are now being used to tailor treatment decisions in patients. However, the application of these tests is far from straightforward, and certain standards are required before any test can be introduced in the daily management of patients. Some of these requirements concern inter-and intratest variability, including whether a test gives the same results if repeated in the same or in another laboratory or when different methodologies are used (e.g. loss of heterozygosity vs fluorescence in situ hybridization and a polymerase chain reaction-based test vs immunohistochemistry). The sensitivity and specificity of a test (or negative and positive predictive value) indicate the likelihood that the test results are positive if the disease is present and the likelihood that the disease is present if the test results are positive. Studies on these test characteristics usually require the presence of a gold standard to which new tests should be compared. Last but not least there is the question of what added value the test has; this criterion determines the clinical usefulness of the assay and why some recently introduced molecular assays need to be scrutinized
- ā¦